Lyxor Stoxx Eurp 600 IndGd&Sv ETF AccA/I (INDP)
After hours:
| Previous close | 2.1800 |
| Open | 2.2200 |
| Bid | 1.5600 x 200 |
| Ask | 2.7200 x 200 |
| Day's range | 2.0486 - 2.2200 |
| 52-week range | 1.5600 - 4.0800 |
| Volume | |
| Avg. volume | 88,364 |
| Market cap | 18.017M |
| Beta (5Y monthly) | 1.23 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -1.8300 |
| Earnings date | 03 May 2024 - 07 May 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 10.00 |
GlobeNewswireIndaptus Therapeutics Presents Positive Mechanism of Action Data at the American Association for Cancer Research Annual Meeting
Results Indicate Decoy Platform Broadly Boosts Immune System's Ability to Fight Tumors Directly and IndirectlyNEW YORK, April 11, 2024 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc, (Nasdaq: INDP), a clinical stage biotechnology company dedicated to pioneering innovative cancer and viral infection treatments, was proud to unveil its poster at the 2024 Annual Meeting of the American Association for Cancer Research (AACR) in San Diego on Wednesday, April 10th. The poster details mechanism of acti
- GlobeNewswire
Indaptus Therapeutics to Present at the MedInvest Biotech and Pharma Investor Conference
NEW YORK, March 28, 2024 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP), a clinical stage biotechnology company dedicated to pioneering innovative cancer and viral infection treatments, announces today that its CEO, Jeffrey Meckler will present a corporate overview at the MedInvest Biotech & Pharma Investor Conference. The conference is being held on April 3 - 4, 2024 at Cooley Law, 55 Hudson Yards, New York, NY 10001. Presentation Date: April 3, 2024Time: 9:55am ETWebcast Link:
- GlobeNewswire
Indaptus Therapeutics Previews Positive Mechanism of Action Data to be Presented at the American Association for Cancer Research Annual Meeting
Data demonstrates that Company’s Decoy platform successfully induces or activates multiple immune cell types involved in anti-tumor responses New data shows activity in M1 macrophages, natural killer cells, dendritic cells, Th1 CD4, and CD8 T cells NEW YORK, March 25, 2024 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc, (Nasdaq: INDP), a clinical stage biotechnology company dedicated to pioneering innovative cancer and viral infection treatments, announces that Dr. Michael Newman, Founder and Ch
